A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Solid Tumors (MK-2140-002)
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Triple-negative Breast Cancer|Non-squamous Non-small-cell Lung Cancer|NSCLC|Estrogen-receptor-positive Breast Cancer|Progesterone-receptor-positive Breast Cancer|Estrogen-receptor-negative Breast Cancer|ER-negative Breast Cancer|Progesterone-receptor Negative Breast Cancer|PR-negative Breast Cancer|HER2-negative Breast Cancer|ER-positive Breast Cancer|PR-positive Breast Cancer|Platinum-resistant Ovarian Cancer|Gastric Cancer|Pancreatic Cancer
Interventions: DRUG: Zilovertamab vedotin
Sponsor: VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)